|
1
|
Raab MS, Podar K, Breitkreutz I, et al:
Multiple myeloma. Lancet. 374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garcia-Sanz R, Mateos MV and San Miguel J:
Multiple myeloma. Med Clin (Barc). 129:104–115. 2007.(In Spanish).
View Article : Google Scholar
|
|
3
|
Krstevska SB, Sotirova T, Balkanov T and
Genadieva-Stavric S: Treatment approach of nontransplant patients
with multiple myeloma. Mater Sociomed. 26:348–351. 2014. View Article : Google Scholar
|
|
4
|
Jakob C, Egerer K, Liebisch P, et al:
Circulating proteasome levels are an independent prognostic factor
for survival in multiple myeloma. Blood. 109:2100–2105. 2007.
View Article : Google Scholar
|
|
5
|
Adams J and Kauffman M: Development of the
proteasome inhibitor Velcade (Bortezomib). Cancer Invest.
22:304–311. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Milacic V, Banerjee S, Landis-Piwowar KR,
Sarkar FH, Majumdar AP and Dou QP: Curcumin inhibits the proteasome
activity in human colon cancer cells in vitro and in vivo. Cancer
Res. 68:7283–7292. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dhillon N, Aggarwal BB, Newman RA, et al:
Phase II trial of curcumin in patients with advanced pancreatic
cancer. Clin Cancer Res. 14:4491–4499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garcea G, Jones DJ, Singh R, et al:
Detection of curcumin and its metabolites in hepatic tissue and
portal blood of patients following oral administration. Br J
Cancer. 90:1011–1015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
von Metzler I, Krebbel H, Kuckelkorn U, et
al: Curcumin diminishes human osteoclastogenesis by inhibition of
the signalosome-associated I kappaB kinase. J Cancer Res Clin
Oncol. 135:173–179. 2009. View Article : Google Scholar
|
|
10
|
Kunnumakkara AB, Anand P and Aggarwal BB:
Curcumin inhibits proliferation, invasion, angiogenesis and
metastasis of different cancers through interaction with multiple
cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kudo C, Yamakoshi H, Sato A, et al: Novel
curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents
with enhanced abilities for multiple myeloma. Anticancer Res.
31:3719–3726. 2011.PubMed/NCBI
|
|
12
|
Li B and Dou QP: Bax degradation by the
ubiquitin/proteasome-dependent pathway: involvement in tumor
survival and progression. Proc Natl Acad Sci USA. 97:3850–3855.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scheffner M, Werness BA, Huibregtse JM,
Levine AJ and Howley PM: The E6 oncoprotein encoded by human
papillomavirus types 16 and 18 promotes the degradation of p53.
Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chng WJ, Price-Troska T, Gonzalez-Paz N,
et al: Clinical significance of TP53 mutation in myeloma. Leukemia.
21:582–584. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang H, Qi C, Yi QL, Reece D and Stewart
AK: p53 gene deletion detected by fluorescence in situ
hybridization is an adverse prognostic factor for patients with
multiple myeloma following autologous stem cell transplantation.
Blood. 105:358–360. 2005. View Article : Google Scholar
|
|
16
|
Avet-Loiseau H, Li JY, Godon C, et al: P53
deletion is not a frequent event in multiple myeloma. Brit J
Haematol. 106:717–719. 1999. View Article : Google Scholar
|
|
17
|
Saha MN, Micallef J, Qiu L and Chang H:
Pharmacological activation of the p53 pathway in haematological
malignancies. J Clin Pathol. 63:204–209. 2010. View Article : Google Scholar
|
|
18
|
Saha MN, Jiang H, Jayakar J, Reece D,
Branch DR and Chang H: MDM2 antagonist nutlin plus proteasome
inhibitor velcade combination displays a synergistic anti-myeloma
activity. Cancer Biol Ther. 9:936–944. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vassilev LT: MDM2 inhibitors for cancer
therapy. Trends Mol Med. 13:23–31. 2007. View Article : Google Scholar
|
|
20
|
Shangary S and Wang S: Targeting the
MDM2-p53 interaction for cancer therapy. Clin Cancer Res.
14:5318–5324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song G, Mao YB, Cai QF, Yao LM, Ouyang GL
and Bao SD: Curcumin induces human HT-29 colon adenocarcinoma cell
apoptosis by activating p53 and regulating apoptosis-related
protein expression. Braz J Med Biol Res. 38:1791–1798. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barlogie B, Zangari M, Spencer T, et al:
Thalidomide in the management of multiple myeloma. Semin Hematol.
38:250–259. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Adams J: Proteasome inhibition in cancer:
development of PS-341. Semin Oncol. 28:613–619. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bharti AC, Donato N, Singh S and Aggarwal
BB: Curcumin (diferuloylmethane) down-regulates the constitutive
activation of nuclear factor-kappa B and IkappaBalpha kinase in
human multiple myeloma cells, leading to suppression of
proliferation and induction of apoptosis. Blood. 101:1053–1062.
2003. View Article : Google Scholar
|
|
25
|
Child JA, Morgan GJ, Davies FE, et al;
Medical Research Council Adult Leukaemia Working Party. High-dose
chemotherapy with hematopoietic stem-cell rescue for multiple
myeloma. N Engl J Med. 348:1875–1883. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sung B, Kunnumakkara AB, Sethi G, Anand P,
Guha S and Aggarwal BB: Curcumin circumvents chemoresistance in
vitro and potentiates the effect of thalidomide and bortezomib
against human multiple myeloma in nude mice model. Mol Cancer Ther.
8:959–970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bharti AC, Takada Y and Aggarwal BB:
Curcumin (diferuloylmethane) inhibits receptor activator of
NF-kappa B ligand-induced NF-kappa B activation in osteoclast
precursors and suppresses osteoclastogenesis. J Immunol.
172:5940–5947. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jana S, Paul S and Swarnakar S: Curcumin
as anti-endometriotic agent: implication of MMP-3 and intrinsic
apoptotic pathway. Biochem Pharmacol. 83:797–804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang ME, Chen YC, Chen IS, Hsieh SC, Chen
SS and Chiu CH: Curcumin protects against thioacetamide-induced
hepatic fibrosis by attenuating the inflammatory response and
inducing apoptosis of damaged hepatocytes. J Nutr Biochem.
23:1352–1366. 2012. View Article : Google Scholar : PubMed/NCBI
|
